2024-10 Primary Care Update Kauai
CE Information
15.0 CME credits (15.0 pharmacology)Completion Time
15 hoursAvailable Until
October 11, 2025Posted By
University Learning SystemsNavigate
Overview
Specialties
Adult and FamilyClinical Topics
COPD, Diabetes, Infectious Disease, Kidney Disease, New Drugs, Obesity, Pharmacology, and Rheumatoid ArthritisSession 1: New Drugs Part 1, Obesity Case Studies, COPD, Fibromyalgia
Session 2: New Drugs Part 2, Pediatric Pharmacotherapeutics, COVID –Drug Interactions, CKD Treatment in Primary Care
Session 3: Antibiotic Update: Respiratory Infections, New Therapies for Resistant Hypertension , OA and RA Guidelines 2023, Immunizations
Learning Objectives
Session 1: New Drugs Part 1, Obesity Case Studies, COPD, Fibromyalgia
New Drugs Part 1
-
Identify 10 – 20 new medications .
-
Discuss the use, side effects, drug-drug interactions, and benefits of each of the medications.
-
Discuss updates related to labeling, indications, risks associated with various medications
Obesity Case Studies:
· Discuss the health risks associated with obesity .
· Identify the various behavioral modalities utilized to assist with weight loss .
· Discuss pharmacologic strategies for weight stabilization or loss in the overweight or obese individual
COPD
· Identify statistics regarding COPD.
· Discuss the signs and symptoms of COPD.
· Discuss treatment options for COPD .
Fibromyalgia
· Identify new diagnostic criteria for fibromyalgia .
· Discuss the various non-pharmacologic and pharmacologic treatments available for individuals with fibromyalgia .
· Review multimodal treatments based upon the evidence .
Session 2: New Drugs Part 2, Pediatric Pharmacotherapeutics, COVID –Drug Interactions, CKD Treatment in Primary Care
New Drugs Part 2
· Identify 10 – 20 new medications
· Discuss the use, side effects, drug-drug interactions, and benefits of each of the medications.
· Discuss updates related to labeling, indications, risks associated with various medications.
Pediatric Pharmacotherapeutics:
· Identify ways in which children are different than adults in terms of pharmacotherapeutics
· Discuss common pediatric prescribing errors.
· Discuss strategies to prevent pediatric prescribing errors.
· Identify medications with new pediatric approvals.
COVID–Drug Interactions
· Improve ability to identify disparity gaps in treatment, management, and drug interactions in outpatients with COVID-19.
· Gain greater confidence in their ability to assess and manage outpatients with COVID-19 for drug interactions.
· Enhance their understanding of the national COVID-19 Treatment Guidelines for outpatients with COVID-19.
CKD Treatment in Primary Care
· Detect and recognize CKD in patients with reduced kidney function, including in early stages of disease.
· Implement screening for albuminuria in patients with diabetes in clinical practice to identify CKD as early as possible.
· Initiate therapy with evidence-based therapies, including newer agents, for patients with CKD when indicated.
Session 3: Antibiotic Update: Respiratory Infections, New Therapies for Resistant Hypertension , OA and RA Guidelines 2023, Immunizations
Antibiotic Update: Respiratory Infections:
· Identify statistics related to incidence/prevalence of various respiratory conditions.
· Discuss the signs and symptoms of pneumonia, ABRS, AOM, AECB.
· Discuss treatment pharmacologic options for the above conditions.
New Therapies for Resistant Hypertension:
· Discuss the definition of resistant hypertension .
· Identify the work up for the patient with resistant hypertension.
· Discuss the treatment options for patient with resistant hypertension .
OA and RA Guidelines 2023
· Discuss the pathophysiology of osteoarthritis and rheumatoid arthritis.
· Identify the non-pharmacologic and pharmacologic agents available for the treatment of osteoarthritis and RA.
· Compare and contrast newer pharmacologic agents with older agents with regard to benefits, risks, side effects, and drug interactions.
Immunizations:
· Identify the 2024 recommended vaccinations and schedule for individuals across the lifespan.
· Discuss the benefits and side effects of the various vaccines for individuals across the lifespan.
· Discuss strategies to improve vaccine hesitancy
Speakers

Owner and Family Nurse Practitioner, Wright & Associates Family Healthcare
Wendy received her Doctor of Nursing Practice in 2019 from the University of Alabama, Tuscaloosa. She is a 1992 graduate of the Adult Primary Care Nurse Practitioner program at Simmons College in Boston and completed a family nurse practitioner post-master’s program in 1995. She is an adult and family nurse practitioner and the owner of two nurse practitioner-owned and -operated clinics within New Hampshire named Wright & Associates Family Healthcare. Her family practices have won numerous awards, including Top Providers in New Hampshire 2018, Top 20 Fastest Growing Family Business, and Top 20 Women-Owned Business in New Hampshire. In addition, she is the Owner of Partners in Healthcare Education, a medical education company. She is the Past President of NPACE and the Senior lecturer for Fitzgerald Health Education Associates. She is the recipient of numerous awards and was chosen by the American Association of Nurse Practitioners as the 1999 recipient of the New Hampshire State Excellence Award. In addition, she received the 2009 New Hampshire Nurse Practitioner of the Year and the 2014 Top 5 Women in New Hampshire Business Award. In 2005, she was inducted as a Fellow into the American Academy of Nurse Practitioners; in October 2014, a Fellow in the American Academy of Nursing; and in March 2017, a Fellow into the National Academies of Practice. She is the founder of the New Hampshire Chamber of Entrepreneurial Nurse Practitioners, an organization designed to assist nurse practitioners with independent practice issues. In addition to full-time clinical practice, she presents nationally to different audiences and has been a speaker at over 1,000 conferences in 47 states. She is the nurse practitioner representative to the State of New Hampshire Immunization Advisory Board. She has been a medical media spokesperson for numerous companies and has appeared on radio, television, and in print magazines. Wendy is frequently consulted by malpractice attorneys around the area of clinical practice and has worked on more than 100 malpractice cases involving nurses and nurse practitioners.
CE Information
This activity offers 15.0 CME credits (15.0 pharmacology) to attendees.
Accredited by ACPE.
PHARMACISTS : University Learning Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
Session |
Contact Hours |
ACPE UAN |
Activity |
Session 1 |
5 | 0741-0000-24-025-H01-P | APPLICATION |
Session 2 | 5 | 0741-0000-24-026-H01-P | APPLICATION |
Session 3 | 5 | 0741-0000-24-027-H01-P | KNOWLEDGE |
NURSE PRACTITIONERS/ NURSES: This course provides 15 contact hours to fulfill the pharmacotherapeutics/ pharmacology requirements for American Nurses Credentialing Center (ANCC) Category 1 Continuing Education Hours for certification renewal as well as other Nurse Practitioner credentialing organizations. The same hours submitted to renew certification may be submitted to a State Board of Nursing for re-licensure. American Nurses Credentialing Center (ANCC) accepts formally approved continuing education sponsored by organizations accredited or approved by the Accreditation Council for Pharmacy Education (ACPE).
PHYSICIANS: This CME program offers Category 2 credit.
PHYSICIAN ASSISTANTS: This CME program offers Category 2 credit.
CONSULTANT PHARMACISTS: Some consultant pharmacist boards accept University Learning Systems courses for recertification either as is or with board approval. Please contact your board regarding course approval and ULS with any questions.
CANADIAN PHARMACISTS: Canadian Council on Continuing Education in Pharmacy (CCCEP) accepts courses accredited by the Accreditation Council for Pharmacy Education (ACPE). This credit is applicable to health professionals who may require pharmacology credit.
CANADIAN PHYSICIANS: Members of the College of Family Physicians of Canada are eligible to receive up to 15 MAINPRO-M1 credits for participation in this activity due to reciprocal agreement with the American Academy of Family Physicians.
OTHER HEALTH PROFESSIONALS: Contact your respective board regarding approval
Disclosures
DR Wright has disclosures with Pfizer, Moderna, Merck, Sanofi, Seqirus, Novavax, AbbVie and Pfizer; Idorsia; Exact Sciences; AstraZeneca.
Ready to start this activity?
Login required. You will be redirected to an external website to register for and complete this activity.
Log in and start activity